242 related articles for article (PubMed ID: 20402541)
1. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis.
Curtis JR; Arora T; Liu Y; Lin TC; Spangler L; Brunetti VC; Stad RK; McDermott M; Bradbury BD; Kim M
J Bone Miner Res; 2024 May; ():. PubMed ID: 38753892
[TBL] [Abstract][Full Text] [Related]
3. The burden of illness of osteoporosis in Canada.
Tarride JE; Hopkins RB; Leslie WD; Morin S; Adachi JD; Papaioannou A; Bessette L; Brown JP; Goeree R
Osteoporos Int; 2012 Nov; 23(11):2591-600. PubMed ID: 22398854
[TBL] [Abstract][Full Text] [Related]
4. Costs of Parkinson's disease in a privately insured population.
Johnson SJ; Kaltenboeck A; Diener M; Birnbaum HG; Grubb E; Castelli-Haley J; Siderowf AD
Pharmacoeconomics; 2013 Sep; 31(9):799-806. PubMed ID: 23907717
[TBL] [Abstract][Full Text] [Related]
5. The burden of illness of osteoporosis in Canadian men.
Tarride JE; Guo N; Hopkins R; Leslie WD; Morin S; Adachi JD; Papaioannou A; Bessette L; Brown JP; Goeree R
J Bone Miner Res; 2012 Aug; 27(8):1830-8. PubMed ID: 22461152
[TBL] [Abstract][Full Text] [Related]
6. Costs of incident non-hip osteoporosis-related fractures in postmenopausal women from a payer perspective.
Barcelos A; Gonçalves J; Mateus C; Canhão H; Rodrigues AM
Osteoporos Int; 2023 Dec; 34(12):2111-2119. PubMed ID: 37596433
[TBL] [Abstract][Full Text] [Related]
7. Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.
Singer A; McClung MR; Tran O; Morrow CD; Goldstein S; Kagan R; McDermott M; Yehoshua A
Arch Osteoporos; 2023 Mar; 18(1):42. PubMed ID: 36905559
[TBL] [Abstract][Full Text] [Related]
8. Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009.
Dalal AA; Liu F; Riedel AA
Int J Chron Obstruct Pulmon Dis; 2011; 6():533-42. PubMed ID: 22069365
[TBL] [Abstract][Full Text] [Related]
9. Surgery for hip fracture yields societal benefits that exceed the direct medical costs.
Gu Q; Koenig L; Mather RC; Tongue J
Clin Orthop Relat Res; 2014 Nov; 472(11):3536-46. PubMed ID: 25091223
[TBL] [Abstract][Full Text] [Related]
10. Utilization and cost of anti-osteoporosis therapy among US Medicare beneficiaries.
Jha S; Bhattacharyya T
Arch Osteoporos; 2016 Dec; 11(1):28. PubMed ID: 27576482
[TBL] [Abstract][Full Text] [Related]
11. Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products.
Lötters FJ; Lenoir-Wijnkoop I; Fardellone P; Rizzoli R; Rocher E; Poley MJ
Osteoporos Int; 2013 Jan; 24(1):139-50. PubMed ID: 22707061
[TBL] [Abstract][Full Text] [Related]
12. Direct costs of common osteoporotic fractures (Hip, Vertebral and Forearm) in Iran.
Rajabi M; Ostovar A; Sari AA; Sajjadi-Jazi SM; Fahimfar N; Larijani B; Daroudi R
BMC Musculoskelet Disord; 2021 Jul; 22(1):651. PubMed ID: 34332559
[TBL] [Abstract][Full Text] [Related]
13. Annual epidemiological and health insurance disease burden of hip osteoarthritis in Hungary based on nationwide data.
Kajos LF; Molics B; Elmer D; Pónusz-Kovács D; Kovács B; Horváth L; Csákvári T; Bódis J; Boncz I
BMC Musculoskelet Disord; 2024 May; 25(1):406. PubMed ID: 38783258
[TBL] [Abstract][Full Text] [Related]
14. Societal costs before and up to 1 year after the first fracture liaison service visit in patients requiring anti-osteoporosis treatments.
Maas L; Boonen A; Wyers CE; Bours S; van den Bergh JP; Evers SM; van Kuijk SMJ; Hiligsmann M
Arch Osteoporos; 2024 May; 19(1):36. PubMed ID: 38740651
[TBL] [Abstract][Full Text] [Related]
15. The High Direct Medical Costs of Prader-Willi Syndrome.
Shoffstall AJ; Gaebler JA; Kreher NC; Niecko T; Douglas D; Strong TV; Miller JL; Stafford DE; Butler MG
J Pediatr; 2016 Aug; 175():137-43. PubMed ID: 27283463
[TBL] [Abstract][Full Text] [Related]
16. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death.
Curtis JR; Arora T; Matthews RS; Taylor A; Becker DJ; Colon-Emeric C; Kilgore ML; Morrisey MA; Saag KG; Safford MM; Warriner A; Delzell E
J Am Med Dir Assoc; 2010 Oct; 11(8):584-91. PubMed ID: 20889095
[TBL] [Abstract][Full Text] [Related]
17. Interstate variation in the burden of fragility fractures.
King AB; Tosteson AN; Wong JB; Solomon DH; Burge RT; Dawson-Hughes B
J Bone Miner Res; 2009 Apr; 24(4):681-92. PubMed ID: 19063680
[TBL] [Abstract][Full Text] [Related]
18. Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma.
Chandra A; Young JS; Dalle Ore C; Dayani F; Lau D; Wadhwa H; Rick JW; Nguyen AT; McDermott MW; Berger MS; Aghi MK
J Neurosurg; 2019 Jun; 133(1):89-99. PubMed ID: 31226687
[TBL] [Abstract][Full Text] [Related]
19. The societal economic burden of autosomal dominant polycystic kidney disease in the United States.
Cloutier M; Manceur AM; Guerin A; Aigbogun MS; Oberdhan D; Gauthier-Loiselle M
BMC Health Serv Res; 2020 Feb; 20(1):126. PubMed ID: 32070341
[TBL] [Abstract][Full Text] [Related]
20. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.
Sato R; Gomez Rey G; Nelson S; Pinsky B
Appl Health Econ Health Policy; 2013 Jun; 11(3):251-8. PubMed ID: 23605251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
